After 6 months, the treated group showed increased levels of MMP-2 and MMP-9, reduced levels of TIMP-1, TIMP-2, and TGF-β/Smad signalling, improved renal fibrosis and enhanced renal function. The gene discussed is TIMP1; the disease is renal fibrosis.